The Use of Transdermal Therapeutic Systems in Psychiatric Care: A Primer on Patches.
Houston, United States. In Psychosomatics, 30 Sep 2015
Such medications include cholinesterase inhibitors for dementia, methylphenidate (MPH) for attention-deficit hyperactivity disorder, monoamine oxidase inhibitors (MAOIs) for depression, dopamine agonists for Parkinson disease and restless leg syndrome, and clonidine for attention-deficit hyperactivity disorder and impulse-control disorders.
Inhibition and oxygen activation in copper amine oxidases.
Bozeman, United States. In Acc Chem Res, Jun 2015
Inhibition of these enzymes by antifungal or antiprotozoal agents, as well as classic monoamine oxidase (MAO) inhibitors, may contribute to the adverse side effects associated with drug treatment.
[Current state and potential of pharmacogenetic studies in the treatment of depression].
In Zh Nevrol Psikhiatr Im S S Korsakova, Dec 2014
The following sections of the review are devoted to the above issues: adrenoreceptors, serotonin transporter protein, dopamine transporter protein, monoamine oxidase A, catechol-O-methyltransferase, brain-derived neurotrophic factor, the hypothalamic-pituitary-adrenal system, G-proteins, the glutamatergic system.
More risk factors generate lower mortality - a useful advice for improved health in the world.
In Bratisl Lek Listy, Dec 2014
The recent data about amelioration of neurodegenerative and other disorders are promising and deserving more work on the issue.ARTICLE HIGHLIGHTSCaffeine is a purine alkaloid from plants and it has a broad use in current pharmacology.Caffeine is a competitive antagonist of neurotransmitter adenosine on adenosine receptors.The substance is added as a supplementary to drugs and food.Besides interfering on adenosine receptors, caffeine interacts with acetylcholinesterase, monoamine oxidase, phosphodiesterase, ryanodine receptors and others.Current research is devoted to the role of caffeine in neurodegenerative diseases and immunity alteration.New chemical compounds based on caffeine moiety are prepared(Tab.
Pharmacological treatment of Parkinson disease: a review.
Hamilton, Canada. In Jama, May 2014
RESULTS: Although levodopa is the most effective medication available for treating the motor symptoms of Parkinson disease, in certain instances (eg, mild symptoms, tremor as the only or most prominent symptom, aged <60 years) other medications (eg, monoamine oxidase type B inhibitors [MAOBIs], amantadine, anticholinergics, β-blockers, or dopamine agonists) may be initiated first to avoid levodopa-related motor complications.